FacebookTwitterLinkedInContact UsLabrix.com

Advanced Workshop

Las Vegas, NV: February 9-11, 2018

Early Bird Discount: Save $50

Interested in gaining a deeper understanding of how hormone and neurotransmitter imbalances are affecting your patient’s health? Register today for the Labrix Advanced Workshop to lock in your early bird discount price of $229, a savings of $50! Includes a Free NeuroAdrenal Panel (Value $215).

 

Core Training

Core Training is designed for practitioners who are new to the field of neuroendrocrine testing and optimization, including BHRT, or are new to using Labrix. Registration for next year's core events will be made available soon. Click here for more information.

 

Wellness Wednesday

Webinar Series

Topic: Adrenal Function & Dysfunction

December 6, 2017

Join Labrix clinical staff and special guests on the first Wednesday of every month at 9:30 AM and 12:00 PM PST. This free, live webinar series will cover a variety of neuroendocrine topics that will enhance your knowledge, with clinically applicable testing and treatment considerations.

OANP

Portland, OR: December 2-3, 2017

Come visit the Labrix booth at the Oregon Association of Naturopathic Physicians in Portland, OR next month.

 

A4M

Las Vegas, NV: December 14-16, 2017

Make sure to visit the Labrix and Doctor's Data booth at A4M in Las Vegas in mid-December. Chat with Labrix co-founders and account representatives to learn what's new at both laboratories.

 

PracticalCME Webinar

Webinar Series

Choose from two LIVE Online Training Webinars with world-class hormone and neurotransmitter expert Gregory Zengo, MD. These full-day courses include up to 8 hours of CME credit and up to 6 months of private consultations with Dr. Zengo. 

Bioidentical Hormone Training Course 

Covers how to accurately test Male hormones, Female hormones, Adrenal function, Thyroid function and treat the most common imbalances including prescribing Bio-Identical Hormones, treating adrenal fatigue, menopause and andropause. The course even includes hands on tips for integrating BHRT into your practice with customizable office forms and advertising materials

 

GABA: An Emerging Treatment for Type 1 Diabetes

 

Published on 11/22/17

Excessive loss of functional pancreatic β-cells is a major factor in the development of hyperglycemia of both type 1 and type 2 diabetics. Despite modest advancements in diabetes management, patients have a shortened life expectancy and lower quality of life when compared to healthy individuals. Other than exogenous insulin therapy, the field of medicine has very few treatment options for type 1 diabetics (T1D). However, recent work has uncovered GABA as a molecule with promising therapeutic potential.

GABA (gamma aminobuteric acid) is the major inhibitory neurotransmitter of the central nervous system and is synthesized from glutamate in the presence of pyridoxal-5-phosphate. GABA is also present in peripheral organs, such as the testes, gastrointestinal tract, ovaries, placenta, uterus, and adrenal medulla, as well as the pancreas, where it’s concentration is the highest and comparable to that in the CNS. GABA is produced by islet β-cells of the pancreas where it regulates islet-cell secretion and function. The synthesizing enzyme, known as glutamate decarboxylase (GAD), is a primary target of autoantibodies, and anti-GAD antibodies are associated with the development of T1D. 

Previous studies have shown GABA therapy to preserve β-cell mass and prevent diabetes in T1D mouse models. Moreover, in severely diabetic mice, GABA therapy has been shown to regenerate β-cell mass and completely reverse hyperglycemia. This seems to be due to both anti-inflammatory and immunoregulatory properties of GABA, relevant in that T1D is thought to be due to autoimmune destruction of β-cells. In fact, GABA has been shown to protect beta cells against apoptosis due to cytokines, drugs and stressors.

A study published in January of this year showed long term GABA therapy to convert pancreatic α-cells (which normally produce glucagon) into β-like cells. These β-like cells were functional (insulin producing) and repeatedly reversed chemically induced diabetes in vivo. Additionally, the study showed concomitant α-cell neogenesis. Mice in this study were given 1-6 months of GABA treatment at 250 ug/kg with daily intraperitoneal injection. The GABA treatment counteracted the consequences of chemically induced diabetes, even in animals who were severely diabetic with blood glucose levels of 300 mg/dL. Xenotransplantation of human islets to rodents models in vivo revealed GABA to continue the β-cell regenerative effects. The regenerative capacity of glucagon producing cells and their potential to convert into beta-like cells are of great interest in the context of T1D research. However, to date, these approaches do not translate to diabetes treatment in humans, though a deeper understanding of human transgenics may lead to more applicable human therapy. 

Imbalanced neurotransmitters levels are typically associated with mood disorders, though these studies suggest a much broader impact of neurotransmitters on pathological processes. The future has yet to unfold the discovery of additional disease processes which may be impacted with neurotransmitter therapies. The GABAergic system, a well-known target of autoimmunity, appears to be a promising tool for β-cell regeneration and the use of neurotransmitter testing will likely broaden, providing information relevant to some of the most impactful treatments of our time.

If you are interested in utilizing neurotransmitter testing, Labrix offers the NeuroBasic panel, along with Neurohormone panels to elucidate neurotransmitter and hormonal imbalances. Labrix is honored to be a part of your practice, improving the lives of patients within the ever-expanding field of functional medicine. 

Labrix Advanced Workshop (LAW) is just around the corner! Join us in Las Vegas, NV, Feb 9-11, 2018.  Includes a FREE NeuroAdrenal Panel. Sign up before Dec. 1 and get $50 off. www.labrix.com/law

 

Resources

Ben-othman N, Vieira A, Courtney M, et al. Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis. Cell. 2017;168(1-2):73-85.e11.

Erdö SL, Wolff JR. gamma-Aminobutyric acid outside the mammalian brain. J Neurochem. 1990;54(2):363-72.

Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J. 1991;10(5):1275-84.

Soltani N, Qiu H, Aleksic M, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci USA. 2011;108(28):11692-7

Wan Y, Wang Q, Prud'homme GJ. GABAergic system in the endocrine pancreas: a new target for diabetes treatment. Diabetes Metab Syndr Obes. 2015;8:79-87. 

 

Labrix Live Trainings

Join the hundreds of practitioners who have attended Labrix live training events and learn more about these exciting opportunities directly from a Labrix attendee and Dr. Jay Mead, Medical Director and co-founder of Labrix.